4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-21-020250
Executive VP, Head of R&D gave up 2,141 shares (to pay taxes)
- Executive VP, Head of R&D acquired 4,583 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Ho Tony W Executive VP, Head of R&D | 2021-03-10 | Option exercise | +4,583 | 40,445 | D: show line 1 in the form | ||
| Ho Tony W Executive VP, Head of R&D | 2021-03-10 | Shares withheld for taxes | −2,141 | $124.15 | $265,805 | 38,304 | D: show line 2 in the form |
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Ho Tony W Executive VP, Head of R&D | 2021-03-11 | Grant or award · Stock Option (Right to Buy) | +23,334 | 23,334 | D: show line 3 in the form | ||
| Ho Tony W Executive VP, Head of R&D | 2021-03-11 | Grant or award · Restricted Stock Units | +9,000 | 9,000 | D: show line 4 in the form |
Loading xslF345X03/doc4.xml…